Florbetapir F 18 Brand Name– Amyvid
What is Florbetapir F 18
Florbetapir F 18 is an intravenous, radioactive, diagnostic agent used to estimate beta-amyloid neuritic plaque density.
It is approved for use with Positron Emission Tomography (PET) brain imaging to evaluate adults for Alzheimer’s Disease (AD) or other causes of cognitive decline. A positive PET scan is indicated by the presence of moderate (6?19) to frequent (>= 20) beta-amyloid plaques; a negative scan indicates sparse (1?5) to no plaques.
A study has shown that readers undergoing special training were able to interpret the scans with 92% sensitivity and 100% specificity.
Florbetapir F 18 PET imaging is only intended for use as an adjunct to other diagnostic tests and does not establish a diagnosis of AD or other cognitive disorders. Additionally, the images cannot be used to predict development of neurologic conditions nor response to therapy.
Florbetapir F 18 was approved by the FDA in April 2012.
Indications
- positron emission tomography (PET) imaging
For use during positron emission tomography (PET) imaging of the brain to estimate beta-amyloid plaque density in adults being evaluated for Alzheimer’s Disease and other causes of cognitive decline
Side Effects
- anxiety
- back pain
- chills
- dizziness
- dysgeusia
- fatigue
- flushing
- headache
- hypertension
- injection site reaction
- insomnia
- musculoskeletal pain
- nausea
- pruritus
- rash
- urticaria
Monitoring Parameters
- pregnancy testing
Contraindications
- accidental exposure
- breast-feeding
- pregnancy
- pregnancy testing
- reproductive risk
Interactions
There are no drug interactions associated with Florbetapir F 18 products.
